Insulin analogues in type 1 diabetes mellitus: getting better all the time (Q38692387)

5 September 2017

title

Insulin analogues in type 1 diabetes mellitus: getting better all the time (English)

1 reference

5 September 2017

0 references

Pieter Gillard

2

0 references

Chantal Mathieu

series ordinal

1

object named as

Chantal Mathieu

1 reference

5 September 2017

Katrien Benhalima

3

1 reference

5 September 2017

publication date

21 April 2017

1 reference

Nature Reviews Endocrinology

5 September 2017

published in

1 reference

5 September 2017

volume

13

1 reference

5 September 2017

issue

7

1 reference

5 September 2017

page(s)

385-399

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

5 September 2017

1 reference

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Monomeric insulins and their experimental and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Efficacy and safety of insulin glulisine in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Stability and performance of rapid-acting insulin analogs used for continuous subcutaneous insulin infusion: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Insulin glulisine: a faster onset of action compared with insulin lispro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with Type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

8. Pharmacologic Approaches to Glycemic Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Glycemic Control and Pregnancy Outcomes in Women with Type 1 Diabetes Mellitus Using Lispro Versus Regular Insulin: A Systematic Review and Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Laboratory-based non-clinical comparison of occlusion rates using three rapid-acting insulin analogs in continuous subcutaneous insulin infusion catheters using low flow rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Pharmacokinetics and pharmacodynamics of basal insulins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Pancreatic beta-cell growth and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Modeling phasic insulin release: immediate and time-dependent effects of glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferior

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Insulin detemir, does a new century bring a better basal insulin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Effect of subcutaneous insulin detemir on glucose flux, lipolysis and electroencephalography in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Safety of Insulin Glargine Use in Pregnancy: A Systematic Review and Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Diabetes and pregnancy: an endocrine society clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Initiation of insulin glargine in children and adolescents with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Treatment with insulin detemir or NPH insulin in children aged 2-5 yr with type 1 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Analysis of 24-hour glycemic excursions in patients with type 1 diabetes by using continuous glucose monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Pharmacokinetics of the Long-Acting Basal Insulin LY2605541 in Subjects With Varying Degrees of Renal Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U/mL compared with glargine 100U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Insulin stacking versus therapeutic accumulation: understanding the differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

A review of the pharmacological properties of insulin degludec and their clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

PEGylated insulin Lispro, (LY2605541)--a new basal insulin analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

How Can a Good Idea Fail? Basal Insulin Peglispro [LY2605541] for the Treatment of Type 2 Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST® T1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

A review of a family of ultra-rapid-acting insulins: formulation development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Design of non-standard insulin analogs for the treatment of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Moving toward the ideal insulin for insulin pumps

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Pursuit of a perfect insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Proinsulin-transferrin fusion protein as a novel long-acting insulin analog for the inhibition of hepatic glucose production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Insulin fibrillation and protein design: topological resistance of single-chain analogs to thermal degradation with application to a pump reservoir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Cell factories for insulin production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Inhaled insulin: a breath of fresh air? A review of inhaled insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Oral insulin delivery: how far are we?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Efficacy of continuous glucose monitoring system (CGMS) to detect postprandial hyperglycemia and unrecognized hypoglycemia in type 1 diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Insulin pens and new ways of insulin delivery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRENDO.2017.39

Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28429780

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Italian multicentre study of intensive therapy with insulin lispro in 1184 patients with Type 1 diabetes

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28429780

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28429780

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRENDO.2017.39

1 reference

5 September 2017

1 reference